[CARA] Cara Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 135.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 9.97 Change: 0.77 (8.37%)
Ext. hours: 10.13 Change: 0.16 (1.6%)

chart CARA

Refresh chart

Strongest Trends Summary For CARA

CARA is in the long-term up 151% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase II clinical trials for the treatment acute postoperative pain in adult patients. The company is also developing Oral CR845 that has completed Phase I clinical trial for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial for treating neuropathic and inflammatory pain. Cara Therapeutics, Inc. was founded in 2004 and is based in Shelton, Connecticut.

Fundamental Ratios
Shares Outstanding27.28 M EPS-2.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -49.06% Sales Growth - Q/Q-46.5% P/E-6.79
P/E To EPS Growth P/S38.79 P/BV2.85 Price/Cash Per Share
Price/Free Cash Flow ROA-36.88% ROE-40.17% ROI
Current Ratio14.31 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin-555.3% Net Profit Margin-546.19% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-10 K Cash From Operating Activities-5.24 M Gross Profit
Net Profit-4.69 M Operating Profit-4.72 M Total Assets51.65 M Total Current Assets49.06 M
Total Current Liabilities3.43 M Total Debt800 K Total Liabilities4.23 M Total Revenue490 K
Technical Data
High 52 week23.95 Low 52 week11.6 Last close19.03 Last change-0.68%
RSI46.55 Average true range0.99 Beta1.6 Volume1.26 M
Simple moving average 20 days0.06% Simple moving average 50 days0.02% Simple moving average 200 days4.44%
Performance Data
Performance Week1.17% Performance Month5.31% Performance Quart11.61% Performance Half0.69%
Performance Year53.47% Performance Year-to-date46.38% Volatility daily2.89% Volatility weekly6.46%
Volatility monthly13.24% Volatility yearly45.87% Relative Volume252.99% Average Volume692.03 K
New High New Low


2019-12-06 16:01:10 | Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

2019-12-04 10:02:03 | Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

2019-12-04 07:14:09 | Investors Who Bought Cara Therapeutics NASDAQ:CARA Shares Three Years Ago Are Now Up 78%

2019-12-03 16:01:10 | Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

2019-12-03 08:41:17 | Benzinga Pro's Top 6 Stocks To Watch For Tues., Dec. 3, 2019: CARA, VRAY, LE, KOD, FXI, ROKU

2019-12-03 07:35:00 | UPDATE: Cara Therapeutics announces positive results in trial of treatment for chronic kidney disease

2019-12-03 07:00:10 | Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

2019-11-18 13:03:03 | Top Marijuana Stocks for November 2019

2019-11-13 09:12:02 | Is the Options Market Predicting a Spike in Cara Therapeutics CARA Stock?

2019-11-12 16:01:00 | Cara Therapeutics to Present at November Investor Conferences

2019-11-11 07:00:00 | Cara Therapeutics Announces Publication of Difelikefalin KORSUVA™ Injection KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine

2019-11-06 04:08:22 | Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT

2019-11-05 18:35:11 | Cara Therapeutics CARA Reports Q3 Loss, Tops Revenue Estimates

2019-11-05 16:01:00 | Cara Therapeutics Reports Third Quarter 2019 Financial Results

2019-11-01 07:00:05 | Cara Therapeutics Announces Presentations at Kidney Week 2019

2019-10-29 16:01:05 | Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

2019-10-29 10:32:02 | Analysts Estimate Cara Therapeutics CARA to Report a Decline in Earnings: What to Look Out for

2019-10-28 19:55:55 | Here’s What Hedge Funds Think About Casa Therapeutics Inc CARA

2019-10-20 08:45:42 | Have Insiders Been Selling Cara Therapeutics, Inc. NASDAQ:CARA Shares?

2019-10-14 07:00:00 | Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

2019-10-01 14:23:51 | First cannabis cafe in the U.S. opens in Los Angeles

2019-09-26 16:01:00 | Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

2019-09-19 10:11:28 | How Much Of Cara Therapeutics, Inc. NASDAQ:CARA Do Institutions Own?

2019-08-21 16:24:33 | Cara Therapeutics Inc CARA Q2 2019 Earnings Call Transcript

2019-08-21 11:44:43 | 10 Marijuana Stocks That Could See 100% Gains, If Not More

2019-08-21 07:04:00 | Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

2019-08-21 07:00:00 | Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

2019-08-19 12:34:11 | Does Cara Therapeutics, Inc.'s NASDAQ:CARA CEO Pay Reflect Performance?

2019-08-08 05:37:56 | Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-05 10:21:00 | Here's Why Cara Therapeutics Rose 11.3% in July

2019-08-05 07:21:00 | Only These 9 Cannabis Stocks Rose in July

2019-07-31 16:01:00 | Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

2019-07-29 16:01:00 | Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-07-26 21:18:00 | Weekly Cannabis Stock News: Auxly's Surprise Strategic Partner Investment

2019-07-25 11:59:00 | Cara Therapeutics Floats New Stock Issue

2019-07-24 20:42:45 | Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

2019-07-24 16:01:00 | Cara Therapeutics Announces Proposed Offering of Common Stock

2019-07-22 07:00:00 | Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

2019-07-17 19:15:03 | Cara Therapeutics Inc CARA CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares

2019-07-16 10:28:34 | 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts

2019-07-14 07:30:00 | 3 Top Biotech Stocks to Buy for the 2nd Half of 2019

2019-07-13 07:56:07 | Estimating The Fair Value Of Cara Therapeutics, Inc. NASDAQ:CARA

2019-07-12 18:27:33 | GuruFocus Value Idea Contest Sees 2 Winners!

2019-07-11 08:30:00 | Enteris BioPharma's _Feasibility-to-Licensing_ Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

2019-07-09 07:00:00 | Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ CR845/difelikefalin for Pruritus in Patients with Atopic Dermatitis

2019-07-02 07:16:00 | Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

2019-06-26 07:00:00 | Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA?? CR845/difelikefalin for Pruritus in Patients with Primary Biliary Cholangitis PBC

2019-06-02 09:09:00 | Is Cara Therapeutics a Buy Now?

2019-05-31 07:00:00 | Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference

2019-05-30 07:48:11 | Cara Shares Up on Positive Phase III Data for Itchiness Drug